Cannara Biotech Inc. (“Cannara Biotech” or the “Company”) (CSE: LOVE) (FRA: 8CB), a vertically integrated cannabis company focused on cultivation and cannabis-infused products, today announced its common shares are listed for trading on the Frankfurt Stock Exchange under the trading symbol “8CB”. The Company’s common shares continue to be listed on the Canadian Securities Exchange under the trading symbol “LOVE”.
Cannara Biotech Inc. (“Cannara Biotech” or the “Company”) (CSE: LOVE), a Montreal-based company that is building a vertically integrated cannabis company focused on cultivation and cannabis-infused products, today announced it has entered into a letter of intent with a leading Quebec microbrewery to develop cannabinoid-infused beverages. Following the regulations relating to edibles and beverages coming into effect next October, consumers will be able to purchase a variety of cannabinoid-infused beverages including non-alcoholic beer, kombucha and cider.
Cartier Resources’ (V.ECR) most recent press release on the “deep results” from its drilling of target 6N1 at the Chimo Mine in Quebec just confirmed what Cartier CEO Philippe Cloutier had anticipated.
At the request of IIROC, the Company wishes to retract and clarify certain disclosure in its January 15, 2019 news release. Specifically, the disclosure “doubling resource potential” is a violation of NI 43-101, 2.3(1)(a) – Restricted Disclosure, as “resource potential” is not a recognized term for Canadian securities legislation, nor can “resource potential” be “doubled” and is therefore misleading. All references to “resource potential” and “doubling resource potential” are retracted. The drill results disclosed in the news release should have been disclosed as exploration results and are accordingly clarified in this release.
FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) would like to congratulate Cannara Biotech Inc. (“Cannara”) for its listing approval and commencement of trading on the Canadian Securities Exchange (“CSE”) today under the stock symbol “LOVE”. FSD Pharma, directly or indirectly, acquired ownership of 85,003,750 common shares (“Common Shares”) of the Issuer, representing 12.25% of the issued and outstanding Common Shares of the Issuer.